Search

Your search keyword '"Banks, Rosamonde E"' showing total 485 results

Search Constraints

Start Over You searched for: Author "Banks, Rosamonde E" Remove constraint Author: "Banks, Rosamonde E"
485 results on '"Banks, Rosamonde E"'

Search Results

1. Geographic variation of mutagenic exposures in kidney cancer genomes

2. Multi-ancestry genome-wide association study of kidney cancer identifies 63 susceptibility regions

3. Transcriptome- and proteome-wide association studies identify genes associated with renal cell carcinoma

5. National Unified Renal Translational Research Enterprise: Idiopathic Nephrotic Syndrome (NURTuRE-INS) study

6. Morphological findings in frozen non-neoplastic kidney tissues of patients with kidney cancer from large-scale multicentric studies on renal cancer

7. Dysregulation at multiple points of the kynurenine pathway is a ubiquitous feature of renal cancer: implications for tumour immune evasion

8. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM)

11. Sex specific associations in genome wide association analysis of renal cell carcinoma

12. Standard Versus Modified Ipilimumab, in Combination With Nivolumab, in Advanced Renal Cell Carcinoma: A Randomized Phase II Trial (PRISM).

13. Associations with age and glomerular filtration rate in a referred population with chronic kidney disease: Methods and baseline data from a UK multicentre cohort study (NURTuRE-CKD)

14. Supplementary Methods S1 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

15. Figure S3 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

16. Supplementary Tables S3-S13 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

17. Supplementary Table S2 from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

18. Data from Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

19. Supplementary Data from Analysis of VHL Gene Alterations and their Relationship to Clinical Parameters in Sporadic Conventional Renal Cell Carcinoma

20. Supplementary Figures 4 - 8 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

21. Data Supplement from The Combination of Circulating Ang1 and Tie2 Levels Predicts Progression-Free Survival Advantage in Bevacizumab-Treated Patients with Ovarian Cancer

22. Supplementary Tables 1 - 8 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

23. Supplementary Figure Legend from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

24. Supplementary Figures 1 - 3 from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

25. Supplementary Methods from Predicting Response to Bevacizumab in Ovarian Cancer: A Panel of Potential Biomarkers Informing Treatment Selection

26. Supplementary Table 2 from Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer

27. Supplementary Table 1 from Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer

28. Data from Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma

29. Supplementary Table 1 from Tumor Suppressor Activity and Epigenetic Inactivation of Hepatocyte Growth Factor Activator Inhibitor Type 2/SPINT2 in Papillary and Clear Cell Renal Cell Carcinoma

30. Supplementary Table 3 from Genetic and Epigenetic Analysis of von Hippel-Lindau (VHL) Gene Alterations and Relationship with Clinical Variables in Sporadic Renal Cancer

31. PRISM protocol: a randomised phase II trial of nivolumab in combination with alternatively scheduled ipilimumab in first-line treatment of patients with advanced or metastatic renal cell carcinoma

32. Application of Genomic Sequencing to Refine Patient Stratification for Adjuvant Therapy in Renal Cell Carcinoma

33. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events After Hospitalization: Findings From the ASSESS-AKI and ARID Studies

34. A deep learning system accurately classifies primary and metastatic cancers using passenger mutation patterns

35. Combined burden and functional impact tests for cancer driver discovery using DriverPower

36. Integrative pathway enrichment analysis of multivariate omics data

37. Pathway and network analysis of more than 2500 whole cancer genomes

38. Divergent mutational processes distinguish hypoxic and normoxic tumours

39. Genomic footprints of activated telomere maintenance mechanisms in cancer

41. Abstract LB113: Genomic classification to refine prognosis in clear cell renal cell carcinoma

44. The influence of obesity-related factors in the etiology of renal cell carcinoma-A mendelian randomization study

47. Plasma Soluble Tumor Necrosis Factor Receptor Concentrations and Clinical Events after Hospitalization: Findings from ASSESS-AKI and ARID studies

Catalog

Books, media, physical & digital resources